KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Deferred Tax (2016 - 2025)

Biomarin Pharmaceutical's Long-Term Deferred Tax history spans 16 years, with the latest figure at $1.5 billion for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 1.3% year-over-year to $1.5 billion, compared with a TTM value of $1.5 billion through Dec 2025, up 1.3%, and an annual FY2025 reading of $1.5 billion, up 1.3% over the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $1.5 billion at Biomarin Pharmaceutical, roughly flat from $1.5 billion in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $1.5 billion in Q1 2024, with the low at $1.4 billion in Q2 2025.
  • Average Long-Term Deferred Tax over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2022.
  • Year-over-year, Long-Term Deferred Tax surged 164.71% in 2021 and then dropped 7.64% in 2025.
  • Tracing BMRN's Long-Term Deferred Tax over 5 years: stood at $1.5 billion in 2021, then increased by 3.81% to $1.5 billion in 2022, then rose by 2.68% to $1.5 billion in 2023, then dropped by 3.65% to $1.5 billion in 2024, then increased by 1.3% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Long-Term Deferred Tax are $1.5 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.4 billion (Q2 2025).